Respiratory syncytial virus vaccine - Artificial Cell Technologies
Alternative Names: Peptide microparticle vaccine for RSV - Artificial Cell Technologies; RSV microparticle vaccine - Artificial Cell Technologies; RSV vaccine - Artificial Cell Technologies (ACT)Latest Information Update: 30 Oct 2021
Price :
$50 *
At a glance
- Originator Artificial Cell Technologies
- Class Peptide vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in USA